Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"HTL Biotechnology","sponsor":"Eirion Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eirion Therapeutics Announces Strategic Agreement for HTL Biotechnology to Become Eirion's Exclusive Botulinum API Manufacturer","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"HTL Biotechnology","sponsor":"GelMEDIX","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HTL Announces Its Incubator's Equity Investment In GelMEDIX, An Early-Stage Biotech Aiming At Revolutionizing Ocular And Regenerative Therapies","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by HTL Biotechnology

    Menu

    HTL Biotechnology

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    Key Products KEY PRODUCTS

    SERVICES

    Key Services KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              HTL Biotechnology

              Contact Supplier
              • Deals
              Virtual BoothHTL Biotechnology is the world leader in the responsible development and production of pharmaceutical-grade biopolymers.
              Contact Supplier Contact Supplier
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              HTL Announces Its Incubator's Equity Investment In GelMEDIX, An Early-Stage Biotech Aiming At Revolutionizing Ocular And Regenerative Therapies

              Details:

              This investment supports development of the GelMEDIX platform, which enables the delivery of therapeutics from small molecules to cell and gene therapies. HTL will produce methacrylate hyaluronic acid, a key component for specific parameters across the GelMEDIX pipeline.

              Lead Product(s): Regenerative Medicine,Hyaluronic Acid

              Therapeutic Area: Ophthalmology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Undisclosed

              Recipient: GelMEDIX

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Financing March 10, 2022

              HTL Biotechnology Biopolymer

              AMWC Asia-TDAC

              Exhibiting

              envelop Contact Supplier

              HTL Biotechnology

              Contact Supplier
              • Deals
              Virtual BoothHTL Biotechnology is the world leader in the responsible development and production of pharmaceutical-grade biopolymers.
              Contact Supplier Contact Supplier
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Eirion Therapeutics Announces Strategic Agreement for HTL Biotechnology to Become Eirion's Exclusive Botulinum API Manufacturer

              Details:

              As part of the agreement, HTL will validate and operate botulinum manufacturing facility in US. Botulinum is the active ingredient in Eirion's lead product candidate ET-01, a topical neuromodulator being developed for Crow's Feet wrinkles and primary axillary hyperhidrosis.

              Lead Product(s): Botulinum toxin type A

              Therapeutic Area: Dermatology Product Name: ET-01

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Eirion Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement September 08, 2021

              HTL Biotechnology Biopolymer

              AMWC Asia-TDAC

              Exhibiting

              envelop Contact Supplier

              HTL Biotechnology Biopolymer
              Send me more info on How To Grow My Business Digitally?
              Post Enquiry
              POST ENQUIRY